In a very small clinical trial conducted in the US, every patient with rectal cancer went into remission.

According to a study published in The New England Journal of Medicine, all patients who were given the new drug — Dostarlimab — had no trace of cancer after six months.

The trial was conducted by doctors at New York’s Memorial Sloan Kettering Cancer Center, which resulted in every single one of their tumors disappearing. NPR reports that some scientists say these kinds of results have never been seen in the history of cancer research. Most people had no severe adverse side effects at all.


“Every single patient is now in remission,” Andrea Cercek, an oncologist who helped with the study told CNN.